Chemotherapy Studies in Human Non-Small Cell Lung Cancer Xenografts Transplanted in Immune-Deprived Mice

  • J. Carmichael
  • J. F. Smyth
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Non-small cell lung cancer lines were successfully established in 15/44 (34%) of tumour biopsies, 9 squamous carcinomas, 5 adenocarcinomas and 1 adenosquamous carcinoma. The overall take rate of all tumour fragments implanted in the first man to mouse passage was low (10%) but this improved in subsequent passages to 57%. Growth rates were variable in all xenografts. Histopathological features were maintained through the first 7 passages although minor changes in differentiation were noted. Chemotherapy studies using maximum tolerated doses of all drugs showed minimal single agent activity. Cis-platinum was the most active drug, exhibiting mean specific growth delay of 1.05 doubling times in 6 tumour lines, with less activity observed with 2 platinum analogues. From these growth delay results significant clinical activity would not be expected, showing correlation with clinical observations. These xenografts offer a useful model for the study of non-small cell lung cancer.


Adenosquamous Carcinoma Platinum Analogue Chemotherapy Study Tumour Volume Doubling Time Xenograft Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gralla RJ, Casper ES, Kelsen DP et al: Cisplatin and vindesine combination chemotherapy for advanced carci noma of the lung: A randomised trial investigating two dosage schedules. Ann Intern Med 1981 (95): 414–420PubMedGoogle Scholar
  2. 2.
    Woods RL, Levi JA, Page J et al: Non-small cell lung cancer: A randomised comparison of chemotherapy with no chemotherapy. Proc Am Soc Clin Oncol 1985 (4):C-691Google Scholar
  3. 3.
    Carmichael J, Greg\or A, Cornbleet MA et al: Vindesine and cis-platinum in the treatment of non-small cell lung cancer. Eur J Cancer Clin Oncol 1985 (21): 811–814PubMedCrossRefGoogle Scholar
  4. 4.
    Steel GG: The growth and therapeutic response of human tumours in immune deficient mice. Bull Cancer 1978 (65): 465–472PubMedGoogle Scholar
  5. 5.
    Shorthouse AJ, Smyth JF, Steel GG et al: The human tumour xenograft -a valid model in experimental chemotherapy. Br J Surg 1980 (67): 715–722PubMedCrossRefGoogle Scholar
  6. 6.
    Mattern J et al: Different growth rates of lung tumours in man and their xenografts in nude mice. Eur J Cancer Clin Oncol 1980 (16): 289–291Google Scholar
  7. 7.
    Steel GG, Courtenay VD, Rostom AY: Improved immunesuppression techniques for the xenografting of human tumours. Br J Cancer 1978 (37): 224–230PubMedCrossRefGoogle Scholar
  8. 8.
    Kopper L and Steel GG: The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res 1975 (35): 2704–2713PubMedGoogle Scholar
  9. 9.
    WHO: International histological classification of tumours. No 1.In: Histological typing of lung tumours. Geneva: World Health Organisation 1981 2nd editionGoogle Scholar
  10. 10.
    Lamb D: The pathology and classification of lung cancer. In: Smyth JF (ed) The management of lung cancer. London: Edward Arnold 1984: 19–35Google Scholar
  11. 11.
    Shorthouse AJ. MS Thesis, University of London 1981Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. Carmichael
    • 1
  • J. F. Smyth
    • 1
  1. 1.Imperial Cancer Research Fund, Medical Oncology Unit, Department of Clinical OncologyWestern General HospitalEdinburghScotland, UK

Personalised recommendations